创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

王猛, 沈爱宗. 妊娠期药物性肝损伤研究进展[J]. 药学进展, 2023, 47(2): 101-107. DOI: 10.20053/j.issn1001-5094.2023.02.004
引用本文: 王猛, 沈爱宗. 妊娠期药物性肝损伤研究进展[J]. 药学进展, 2023, 47(2): 101-107. DOI: 10.20053/j.issn1001-5094.2023.02.004
WANG Meng, SHEN Aizong. Research Progress of Drug-induced Liver Injury during Pregnancy[J]. Progress in Pharmaceutical Sciences, 2023, 47(2): 101-107. DOI: 10.20053/j.issn1001-5094.2023.02.004
Citation: WANG Meng, SHEN Aizong. Research Progress of Drug-induced Liver Injury during Pregnancy[J]. Progress in Pharmaceutical Sciences, 2023, 47(2): 101-107. DOI: 10.20053/j.issn1001-5094.2023.02.004

妊娠期药物性肝损伤研究进展

Research Progress of Drug-induced Liver Injury during Pregnancy

  • 摘要: 妊娠期药物性肝损伤(DILI)在临床上较其他人群少见,重者可出现急性肝衰竭,导致患者接受肝移植或死亡,严重威胁母婴结局。近年来,妊娠期DILI越发引起临床重视,因缺乏妊娠期用药安全性研究,以及妊娠期DILI影响因素复杂、诊断困难等原因致使妊娠期DILI的管理面临挑战。综述妊娠期DILI的流行病学、类型、影响因素、常见药物及临床诊断与管理,以期为妊娠期DILI的诊疗管理提供参考。

     

    Abstract: Drug-induced liver injury during pregnancy (DILI), one of the key causes of acute liver failure and even death in pregnant women, seriously impairs maternal and infant outcomes. Nowadays, DILI has received increasing clinical attention due to its uncommon yet serious consequences. The management of DILI faces great challenges due to the lack of studies on the safety of medication during pregnancy, the complex influencing factors, and the difficulty in diagnosis. In this article, the epidemiology, types, influencing factors, common drugs, clinical diagnosis and management of DILI are reviewed to provide a valuable basis for clinical practice.

     

/

返回文章
返回